CurrentAnesthesia — Organ support & nutrition

Extracorporeal Membrane Oxygenation for Refractory Asthma Exacerbations With Respiratory Failure

2026-10-28T04:40:50.491Z

Cohort study · Chest, 2022. Hospital mortality — ECMO vs No ECMO: OR 0.33 (95% CI 0.17-0.64); P = .001; covariate-adjusted

Comparative outcomes of extracorporeal membrane oxygenation for COVID-19 delivered in experienced European centres during successive SARS-CoV-2 variant outbreaks (ECMO-SURGES): an international, multicentre, retrospective cohort study

2026-10-28T04:39:17.656Z

Cohort study · Lancet Respir Med, 2023. 90-day mortality, 90 days: Wild type 297 (43%) · Alpha 152 (39%) · Delta 78 (40%) · Other 42 (58%)

Continued enteral nutrition until extubation compared with fasting before extubation in patients in the intensive care unit: an open-label, cluster-randomised, parallel-group, non-inferiority trial

2026-10-28T04:39:17.656Z

Randomised controlled trial · Lancet Respir Med, 2023. Extubation failure (ITT), 7 days: Continued enteral nutrition 106 (17.2%) · Fasting 90 (17.5%)

Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement

2026-10-28T04:39:17.656Z

Guideline or statement · Lancet Respir Med, 2023.

In-hospital and 6-month outcomes in patients with COVID-19 supported with extracorporeal membrane oxygenation (EuroECMO-COVID): a multicentre, prospective observational study

2026-10-28T04:39:17.656Z

Cohort study · Lancet Respir Med, 2022. In-hospital mortality and 6-month survival: Died in hospital 602 (50%) of 1215

Low versus standard calorie and protein feeding in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group trial (NUTRIREA-3)

2026-10-28T04:39:17.656Z

Randomised controlled trial · Lancet Respir Med, 2023. Day 90 all-cause mortality; time to readiness for ICU discharge (co-primary): Low 628 (41.3%); median time to readiness for ICU discharge (IQR 5.0-14.0) days 8.0 · Standard 648 (42.8%); median time to readiness for ICU discharge (IQR 5.0-17.0) days 9.0

Prognostic factors associated with mortality among patients receiving venovenous extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis

2026-10-28T04:39:17.656Z

Meta-analysis · Lancet Respir Med, 2022. Factors with moderate or high certainty of association with increased mortality — Older age: aHR 2.27 (95% CI 1.63-3.16); patient factor

Transfusion practice in patients receiving VV ECMO (PROTECMO): a prospective, multicentre, observational study

2026-10-28T04:39:17.656Z

Cohort study · Lancet Respir Med, 2022. Daily haemoglobin concentration, haemoglobin at PRBC transfusion, and rate of transfusions: Mean haemoglobin concentration over ECMO days (SD 1.2), lower in North America and high-volume centres 9.1 g/dL

Antimicrobial Exposures in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation

2026-10-28T04:38:28.626Z

Cohort study · Am J Respir Crit Care Med, 2023. Antimicrobial pharmacokinetics (PKs): Large variations in antimicrobial concentrations (coefficient of variation ⩾30%), >fivefold variations in all PK parameters across all study antimicrobials

One-Year Mental and Physical Health Assessment in Survivors after Extracorporeal Membrane Oxygenation for COVID-19–related Acute Respiratory Distress Syndrome

2026-10-28T04:38:28.626Z

Cohort study · Am J Respir Crit Care Med, 2023. Health status at 1 year: All alive

Analysis of urinary C–C motif chemokine ligand 14 (CCL14) and first-generation urinary biomarkers for predicting renal recovery from acute kidney injury: a prospective exploratory study

2026-10-28T04:36:50.728Z

Diagnostic or prognostic study · J Intensive Care, 2023. Prediction of renal non-recovery: CCL14: AUC 0.71 (95% CI 0.63-0.77, p < 0.001) · [TIMP-2] × [IGFBP7]: AUC 0.78 (95% CI 0.71-0.84, p < 0.001) · NGAL: AUC 0.53 (95% CI 0.45-0.60, p = 0.562)

Effectiveness of systemic thrombolysis on clinical outcomes in high-risk pulmonary embolism patients with venoarterial extracorporeal membrane oxygenation: a nationwide inpatient database study

2026-10-28T04:36:50.728Z

Cohort study · J Intensive Care, 2023. In-hospital mortality: Thrombolysis 52% · Control 61%

Extracorporeal membrane oxygenation for COVID-19-related acute respiratory distress syndrome: a narrative review

2026-10-28T04:36:50.728Z

Research article · J Intensive Care, 2023. veno-venous (VV) extracorporeal membrane oxygenation (ECMO) the default choice for refractory respiratory failure; Venoarterial (VA) ECMO or Oxy-RVAD considered with concomitant severe right ventricular dysfunction

Onset timing and duration of augmented renal clearance in a mixed intensive care unit

2026-10-28T04:36:50.728Z

Cohort study · J Intensive Care, 2023. ARC prevalence, onset and duration: Prevalence of ARC 33.4% (245/734)

Accurate and interpretable prediction of ICU-acquired AKI

2026-10-28T04:33:02.462Z

Cohort study · J Crit Care, 2023. AUROC before diagnosis: any-AKI model AUROC 0.756 · moderate-to-severe AKI model AUROC 0.721

Drug-related causes attributed to acute kidney injury and their documentation in intensive care patients

2026-10-28T04:33:02.462Z

Cohort study · J Crit Care, 2023. AKI stage 2 or 3 and DAKI: ICU admissions with AKI stage 2 or 3: 542 6.7%

Early and prolonged continuous hypertonic saline infusion in patients with acute liver failure

2026-10-28T04:33:02.462Z

Cohort study · J Crit Care, 2023. Serum sodium with HTS: HTS median 149 mmol/L · non-HTS median 138 mmol/L

Health-related quality of life, one-year costs and economic evaluation in extracorporeal membrane oxygenation in critically ill adults

2026-10-28T04:33:02.462Z

Cohort study · J Crit Care, 2022. Survival, HRQOL (EQ-5D-5L) and associated healthcare costs in the first year, 1 year: One-year mortality 50%

Optimal positive end-expiratory pressure reduces right ventricular dysfunction in COVID-19 patients on venovenous extracorporeal membrane oxygenation: A retrospective single-center study

2026-10-28T04:33:02.462Z

Cohort study · J Crit Care, 2023. Hemodynamically significant RV dysfunction: Optimal PEEP 4.55% · Standard PEEP 44.0%

Recovery after AKI: Effects on outcomes over 15 years

2026-10-28T04:33:02.462Z

Cohort study · J Crit Care, 2023. 15-year mortality, up to 15 years: Not recovered 57.8% · Recovered 45.2% · No AKI 30.3%

The impact of temporary mechanical circulatory support strategies on thrombocytopenia

2026-10-28T04:33:02.462Z

Cohort study · J Crit Care, 2022. Mean percent platelet drop on implantation: VA ECMO mean -69.6%; p p < 0.001 · VV ECMO mean -40.9%; p p < 0.001 · Impella 5.5 mean -20.9%; p p = 0.01 · IABP mean -28.3%; p p = 0.01 · Centrimag BIVAD mean -6.5%; p p = 0.61

Transient diabetes insipidus in critically ill COVID19 patients

2026-10-28T04:33:02.462Z

Cohort study · J Crit Care, 2023. Transient DI: Patients with DI 12

Critically ill severe hypothyroidism: a retrospective multicenter cohort study

2026-10-28T04:30:32.433Z

Cohort study · Ann Intensive Care, 2023. Mortality: In-ICU mortality 26%

Intravenous vitamin C monotherapy in critically ill patients: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis

2026-10-28T04:30:32.433Z

Meta-analysis · Ann Intensive Care, 2023. Overall mortality — IVVC vs Control: RR 0.73 (95% CI 0.60-0.89); p = 0.002; I2 = 42%

Long-term outcomes after severe acute kidney injury in critically ill patients: the SALTO study

2026-10-28T04:30:32.433Z

Randomised controlled trial · Ann Intensive Care, 2023. Long-term survival, renal outcome and health related quality of life (HRQOL): Overall survival rate at 3 years from inclusion 39.4% (95% CI 35.4 to 43.4)

Analysis of Wholesale Drug Acquisition and Laboratory Assessment Costs Between Heparin Compared With Bivalirudin-Based Systemic Anticoagulation Strategies in Adult Extracorporeal Membrane Oxygenation

2026-10-28T04:21:38.918Z

Cohort study · Crit Care Med, 2023. Costs per ECMO day: AT assay costs per ECMO day: $11.78 [IQR $9.48-$13.09] vs $1.03 [IQR $0-$5.75] (pre vs post) p < 0.0001

Health Disparities in Extracorporeal Membrane Oxygenation Utilization and Outcomes: A Scoping Review and Methodologic Critique of the Literature*

2026-10-28T04:21:38.918Z

Research article · Crit Care Med, 2023. Direction of associations by race, ethnicity, SES or payer (148 studies): Studies including race/ethnicity/SES/payer variables (primary analysis) 148 (68%)

Incidence and Outcomes of Patients Receiving Chronic Kidney Replacement Therapy Admitted to Scottish ICUs Between 2009 and 2019—A National Observational Cohort Study

2026-10-28T04:21:38.918Z

Cohort study · Crit Care Med, 2022. ICU admission rate: Chronic dialysis 59.1 per 1,000 person-years · Kidney transplant 19.9 per 1,000 person-years

Outcomes of Extremely Prolonged (> 50 d) Venovenous Extracorporeal Membrane Oxygenation Support

2026-10-28T04:21:38.918Z

Cohort study · Crit Care Med, 2023. Outcomes of extremely prolonged VV ECMO: Duration of VV ECMO support, median (IQR 70-128 d; maximum 180 days) 94 days

Predicting the Development of Renal Replacement Therapy Indications by Combining the Furosemide Stress Test and Chemokine (C-C Motif) Ligand 14 in a Cohort of Postsurgical Patients

2026-10-28T04:21:38.918Z

Cohort study · Crit Care Med, 2023. Prediction of the primary endpoint at inclusion, At the time of inclusion: FST + CCL14: AUC 0.87 (95% CI, 0.82-0.92) · FST: AUC 0.79 (95% CI, 0.74-0.85) · CCL14: AUC 0.83 (95% CI, 0.77-0.89)

The Role of Cell Cycle Arrest Biomarkers for Predicting Acute Kidney Injury in Critically Ill COVID-19 Patients: A Multicenter, Observational Study

2026-10-28T04:21:38.918Z

Cohort study · Crit Care Med, 2023. Prediction of moderate or severe AKI, At enrollment: (TIMP-2) × (IGFBP7): AUC 0.89 (95% CI, 0.84-0.93)

Association between early nutrition support and 28-day mortality in critically ill patients: the FRANS prospective nutrition cohort study

2026-10-28T04:14:48.087Z

Cohort study · Crit Care, 2023. D28 mortality — Early nutrition vs No early nutrition: crude OR 1.69 (95% CI 1.23-2.34); univariate analysis

CytoSorb hemoperfusion markedly attenuates circulating cytokine concentrations during systemic inflammation in humans in vivo

2026-10-28T04:14:48.087Z

Randomised controlled trial · Crit Care, 2023. Plasma cytokine levels, CytoSorb vs control, first LPS challenge, first LPS challenge (day 0): Tumor necrosis factor (TNF) lower with CytoSorb (p < 0.0001) - 58%

Extracorporeal treatment for ethylene glycol poisoning: systematic review and recommendations from the EXTRIP workgroup

2026-10-28T04:14:48.087Z

Guideline or statement · Crit Care, 2023.

Target attainment and population pharmacokinetics of flucloxacillin in critically ill patients: a multicenter study

2026-10-28T04:14:48.087Z

Cohort study · Crit Care, 2023. Simulated target attainment (ƒT>2 mg/L ≥ 50%): 12 g 26% · 24 g 51%

The Sequential Organ Failure Assessment (SOFA) Score: has the time come for an update?

2026-10-28T04:14:48.087Z

Research article · Crit Care, 2023. SOFA score developed >25 years ago; changes in clinical practice (new interventions, greater focus on non-invasive monitoring) mean it is time to update it

Toward nutrition improving outcome of critically ill patients: How to interpret recent feeding RCTs?

2026-10-28T04:14:48.087Z

Research article · Crit Care, 2023. Recent RCTs: early full nutritional support does not benefit critically ill patients and may induce dose-dependent harm

Daily point-of-care ultrasound-assessment of central venous catheter-related thrombosis in critically ill patients: a prospective multicenter study

2026-10-28T04:13:06.971Z

Cohort study · Intensive Care Med, 2023. Incidence of CRT: CRT incidence 16.9% (95% CI 14.8-18.9%)

Impact of BMI on outcomes in respiratory ECMO: an ELSO registry study

2026-10-28T04:13:06.971Z

Cohort study · Intensive Care Med, 2022. In-hospital mortality — BMI ≥ 35 kg/m2 vs Lean: OR 0.878 (95% CI 0.798-0.966); p = 0.008; Propensity-score (PS)-matched

Prognostic models for mortality risk in patients requiring ECMO

2026-10-28T04:13:06.971Z

Meta-analysis · Intensive Care Med, 2023. Discrimination (pooled c-statistic): SAVE and RESP score pooled c-statistic between 0.66 and 0.70 · SAPS II, APACHE II, SOFA pooled c-statistic between 0.66 and 0.69

Renal outcomes following intravenous contrast administration in patients with acute kidney injury: a multi-site retrospective propensity-adjusted analysis

2026-10-28T04:13:06.971Z

Cohort study · Intensive Care Med, 2023. Persistent AKI at hospital discharge — CM vs No CM: OR 1 (95% CI 0.89-1.11); unadjusted multivariable logistic regression

Development and validation of clinical prediction models for acute kidney injury recovery at hospital discharge in critically ill adults

2026-10-28T04:08:44.882Z

Diagnostic or prognostic study · J Clin Monit Comput, 2022. Discrimination for AKI recovery, validation cohort, hospital discharge: Prediction models: AUROC, complete recovery 0.53; AUROC, complete or partial recovery 0.61 · NGAL_AKI3: AUROC, complete recovery 0.55; AUROC, complete or partial recovery 0.53

Sublingual microcirculation: comparison between the 415 nm blue light and 520 nm green light of sidestream dark field videomicroscopes

2026-10-28T04:08:44.882Z

Diagnostic or prognostic study · J Clin Monit Comput, 2022. Vessel density in healthy volunteers — Blue light vs Green light: increase in perfused vessel density 4.6 ± 4.7 mm/mm2; P < 0.0001; paired t test

Echocardiography Before Extracorporeal Membrane Oxygenation in Refractory Respiratory Failure: SARS-CoV-2 Infection Versus Other Etiologies

2026-10-28T03:56:35.329Z

Cohort study · J Cardiothorac Vasc Anesth, 2023. Pre-ECMO echocardiographic findings: Incidence of RV dilatation higher in COVID-19 series p < 0.001

Preoperative Pulmonary Artery-to-Aorta Diameter Ratio as a Predictor of Postoperative Severe Right Ventricular Failure and 1-Year Mortality After Left Ventricular Assist Device Implantation

2026-10-28T03:56:35.329Z

Cohort study · J Cardiothorac Vasc Anesth, 2023. PA diameter and PA/Ao ratio in severe RVF: Median PA diameter significantly greater in the severe RVF group p = 0.001

Prevalence and Severity of Aortic Regurgitation Due to a Percutaneous Left Ventricular Assist Device (Impella 5.0): A Retrospective Observational Study

2026-10-28T03:56:35.329Z

Cohort study · J Cardiothorac Vasc Anesth, 2022. aortic regurgitation (AR) during Impella 5.0 support (patients with closed aortic valves, no spontaneous CO): Impella 5.0 17 (89.5%); Mild AR 11 (57.9%); Moderate AR 6 (31.6%); Median AR volume 0.6 L/min (IQR 0.4-1.5 L/min); AR as % of median Impella 5.0 flow 13.5% (IQR 11.0 to 30.6%)

Spinal Cord Infarction With Prolonged Femoral Venoarterial Extracorporeal Membrane Oxygenation

2026-10-28T03:56:35.329Z

Cohort study · J Cardiothorac Vasc Anesth, 2023. spinal cord injury (SCI) incidence: Patients with prolonged VA-ECMO who developed SCI 7 (5.3%)

A new machine learning algorithm to predict veno-arterial ECMO implantation after post-cardiotomy low cardiac output syndrome

2026-10-28T03:54:35.559Z

Diagnostic or prognostic study · Anaesth Crit Care Pain Med, 2022. Prediction of VA-ECMO implantation (external validation dataset): External validation dataset: ROC AUC 0.863 (0.793-0.928)

Strategies for intraoperative glucose management: a scoping review

2026-10-28T03:51:30.684Z

Research article · Can J Anaesth, 2022. Characteristics of the evidence on intraoperative glycemic management (included articles, definitions of outcomes and exposures, study populations): Articles meeting inclusion criteria 41

Associations between enteral nutrition and outcomes in the SUP‐ICU trial: Protocol for exploratory post hoc analyses

2026-10-28T03:44:37.230Z

Trial design · Acta Anaesthesiol Scand, 2023. Clinically important GI bleeding